Healthcare Sales & Marketing Network News: Astellas Pharma

Searching News Database: Astellas Pharma

HSMN NewsFeed - 22 Mar 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Nov 2023
Actinium Appoints Lynn Bodarky as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Jun 2023
Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Regenerative Medicine Venture Capital

HSMN NewsFeed - 8 Jun 2023
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Biopharmaceuticals Regenerative Medicine Licensing

HSMN NewsFeed - 20 Jan 2023
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Aug 2022
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Biopharmaceuticals Urology Oncology Regulatory

HSMN NewsFeed - 4 May 2021
Astellas' XTANDI(TM) (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2021
Astellas Announces Positive Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women
Biopharmaceuticals

HSMN NewsFeed - 21 Dec 2020
Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel

HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 May 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 22 Apr 2020
FoRx Therapeutics AG Raises EUR 10 Million Seed Round and Becomes First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory

HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Oct 2019
Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Sep 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 May 2019
Evox Therapeutics Expands Leadership Team With the Appointment of Two Experienced Life Sciences Executives
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology

HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Jan 2019
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jan 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Apr 2018
Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Jan 2018
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2017
ORIC Has Appointed Rich Heyman, PhD as Acting Chief Executive Officer and Leonard Reyno, MD as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Dec 2017
Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma Brasil
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2017
Astellas to Acquire Ogeda SA
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Dec 2016
Mission Therapeutics Appoints Colin Goddard as Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Oct 2016
Astellas to Acquire Ganymed Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Oct 2016
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 28 Sep 2016
Pfizer Completes Acquisition of Medivation
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Sep 2016
Egalet Appoints Patrick Shea as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Feb 2016
Astellas Names James Robinson President, Americas Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Feb 2016
Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients With Cystic Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Jan 2016
Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies
Biopharmaceuticals Venture Capital Mergers & Acquisitions

HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Nov 2015
LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
Biopharmaceuticals Dermatology Acquisitions

HSMN NewsFeed - 3 Apr 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 16 Dec 2014
Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody(TM) Therapeutics Targeting Immune Checkpoint Inhibitors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 4 Aug 2014
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 May 2014
Clarus Therapeutics Appoints Patrick Shea Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2014
Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Apr 2014
Astellas Announces European Regulatory Submission For XTANDI(R) (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Apr 2014
EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics' Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Feb 2014
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution

HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 8 Jan 2014
Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Jan 2014
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 17 Dec 2013
Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 31 Jul 2013
Astellas Appoints New Senior Vice President of Global Oncology Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jul 2013
XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Biopharmaceuticals Distribution

HSMN NewsFeed - 29 May 2013
Amgen And Astellas Announce Japan Alliance
Biopharmaceuticals

HSMN NewsFeed - 24 May 2013
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 May 2013
Astellas Receives Marketing Authorization for VESOMNI(TM) from the Netherlands Medicines Evaluation Board
Biopharmaceuticals Urology Regulatory

HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 13 May 2013
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2013
Royalty Pharma Announces Firm Offer to Acquire Elan
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Jan 2013
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Biopharmaceuticals HIV/AIDS Personnel

HSMN NewsFeed - 18 Sep 2012
Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Aug 2012
Astellas Pharma Europe Ltd. Appoints Dr Susan Wood as Senior Director, Market Access
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Aug 2012
Astellas to Close Urogenix, North Carolina-based Urology Research Facility
Biopharmaceuticals Urology

HSMN NewsFeed - 24 Jul 2012
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jul 2012
Coferon, Inc. Announces $12 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 18 Jun 2012
XenoPort Appoints Ernest Mario, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jan 2012
Astellas Pharma Europe Ltd. Appoints Mike Crooks to Head up its UK Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jan 2012
Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Jan 2012
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2011
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2011
NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Aug 2011
Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2011
NeurogesX CEO Anthony DiTonno to Retire by Year End
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2011
Noven Appoints Lance D. Williams as Vice President of Human Resources
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 10 Jan 2011
Optimer Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2011
Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Dec 2010
Aperio Continues Leadership in Digital Pathology
Devices Diagnostics

HSMN NewsFeed - 14 Dec 2010
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Nov 2010
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
Biopharmaceuticals Drug Delivery Reimbursement

HSMN NewsFeed - 2 Nov 2010
Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jul 2010
Sun Pharma Announces USFDA Approval for Generic Flomax(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 21 Jun 2010
NormOxys Appoints Dr. John A. Hey Senior Vice President of Preclinical and Early Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Jun 2010
Astellas Completes Acquisition of OSI Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Jun 2010
Astellas Announces Successful Completion of Tender Offer for Shares of OSI
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 3 May 2010
Basilea's Toctino(R) receives marketing authorization in Italy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Apr 2010
Qutenza(R) (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 30 Mar 2010
Medivation Announces Reduction in Workforce
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2010
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
Biopharmaceuticals Mergers & Acquisitions Personnel

HSMN NewsFeed - 5 Mar 2010
XenoPort Restructures to Focus on Key Programs
Biopharmaceuticals

HSMN NewsFeed - 2 Mar 2010
OSI Pharmaceuticals Board of Directors to Review Astellas' Unsolicited Tender Offer
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 2 Mar 2010
Impax Laboratories Receives Final FDA Approval for Generic FLOMAX(R) 0.4mg Capsules and Immediately Commences Shipment
Biopharmaceuticals FDA Generics

HSMN NewsFeed - 2 Mar 2010
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Biopharmaceuticals Mergers & Acquisitions Litigation

HSMN NewsFeed - 1 Mar 2010
OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Mar 2010
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Feb 2010
NeurogesX Announces Management Team Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Dec 2009
Cubist Pharmaceuticals to Acquire Calixa Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Dec 2009
NormOxys Appoints Industry Veteran and Recognized Neuroscience Expert, Martin Tolar, MD, PhD, as Company's CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Nov 2009
Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals

HSMN NewsFeed - 5 Nov 2009
NeurogesX Expands Commercial Operations Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Oct 2009
Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Biopharmaceuticals Devices Drug Delivery

HSMN NewsFeed - 13 Oct 2009
Seattle Genetics Names Head of Commercial and Announces Management Promotion
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Sep 2009
Maxygen Announces Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Aug 2009
XenoPort Appoints Dennis Fenton to Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Aug 2009
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Biopharmaceuticals

HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jun 2009
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
Biopharmaceuticals Drug Delivery Distribution

HSMN NewsFeed - 10 Jun 2009
Astellas Names Head of Global R&D Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 May 2009
Astellas Announces New Vice President of Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 May 2009
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Apr 2009
XenoPort Announces Election of Co-Promotion Option for Solzira
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Mar 2009
Astellas to Terminate Offer for CV Therapeutics
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Mar 2009
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 27 Feb 2009
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Feb 2009
Astellas Pharma Issues Statement Regarding CV Therapeutics Rejection of All-Cash Proposal
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 Jan 2009
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 27 Jan 2009
Astellas Proposes to Acquire CV Therapeutics for $16 per Share in Cash
Biopharmaceuticals Cardiology Mergers & Acquisitions

HSMN NewsFeed - 23 Jan 2009
Protopic(R) Ointment (tacrolimus monohydrate) Receives Positive Opinion for Twice-Weekly use (Maintenance Treatment) in the Treatment of Atopic Dermatitis by the European Medicines Agency
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 9 Jan 2009
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Oct 2008
Theron Odlaug, Ph.D. Promoted to Chief Executive Officer at CyDex Pharmaceuticals
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Sep 2008
Seattle Genetics Adds to Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Sep 2008
Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation
Biopharmaceuticals

HSMN NewsFeed - 16 Sep 2008
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 2 Sep 2008
Sucampo Pharmaceuticals Limited Appoints New Head of Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Aug 2008
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Biopharmaceuticals FDA Cardiology

HSMN NewsFeed - 17 Jul 2008
AMT Appoints Director Global Marketing and Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jul 2008
XenoPort Appoints David A. Stamler, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jun 2008
Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
Biopharmaceuticals Radiology Cardiology

HSMN NewsFeed - 22 May 2008
CyDex Pharmaceuticals Appoints Theron (Ted) Odlaug, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 May 2008
Astellas' Mycamine(R) (micafungin) Licensed for Use in Europe to Treat Serious Fungal Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 May 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Apr 2008
APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2008
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Biopharmaceuticals

HSMN NewsFeed - 25 Mar 2008
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Mar 2008
FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Feb 2008
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jan 2008
Cardiome And Astellas Announce Regulatory Update
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Dec 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2007
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals

HSMN NewsFeed - 29 Nov 2007
Sagent Pharmaceuticals Launches Full-Line of Prefilled 6 mg and 12 mg Adenosine Syringes
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
Ranbaxy and Astellas/Boehringer Ingelheim Enter Into an Agreement to Resolve Tamsulosin U.S. Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 8 Nov 2007
Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 7 Nov 2007
Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
Biopharmaceuticals Cardiology

HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2007
Adenoscan(R) Patent Lawsuits Settled
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 22 Oct 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 10 Oct 2007
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals

HSMN NewsFeed - 6 Sep 2007
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 31 Jul 2007
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jul 2007
Cadence Pharmaceuticals Announces Agreement With FDA on Increased Enrollment In Phase III Clinical Trial of Omigard(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jun 2007
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 May 2007
Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 May 2007
CV Therapeutics Submits New Drug Application For Regadenoson
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 1 May 2007
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Apr 2007
Cardiome Announces In-Licensing Agreement With Eli Lilly and Company
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Apr 2007
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2007
Cardiome Announces Appointment of Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Feb 2007
Astellas Receives a Positive CHMP Opinion for EU Marketing Authorisation for FK506 Modified Release as a Once-Daily Immunosuppressant in Organ Transplantation
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Feb 2007
Cardiome Announces Management Appointments
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 20 Feb 2007
Theravance Announces FDA Acceptance of Telavancin NDA
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2007
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
Biopharmaceuticals

HSMN NewsFeed - 29 Jan 2007
Icagen Announces $22 Million Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Jan 2007
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement
Biopharmaceuticals Litigation

HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Biopharmaceuticals

HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2006
Advanced Life Sciences Announces Election of Theron (Ted) E. Odlaug, Ph.D. to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2006
Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Dec 2006
Eligard(R) six-month formulation approved in Germany
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Oct 2006
Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program
Biopharmaceuticals

HSMN NewsFeed - 27 Sep 2006
Cardiome Announces USAN Name And Patent Grant
Biopharmaceuticals Cardiology

HSMN NewsFeed - 12 Sep 2006
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
Biopharmaceuticals

HSMN NewsFeed - 18 Jul 2006
Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
Biopharmaceuticals

HSMN NewsFeed - 28 Jun 2006
Adolor Corporation Appoints Scott T. Megaffin as Vice President, Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2006
Cardiome Announces Refusal To File Decision By The FDA
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 25 May 2006
Icagen Names Senior Vice President Clinical and Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2006
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program With Investigational Antibiotic, Telavancin
Biopharmaceuticals

HSMN NewsFeed - 10 May 2006
Astex Announces New Chief Executive Officer
Biopharmaceuticals Personnel

Return to NewsFeed

Additional items found! 35

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 35 additional stories matching:
Astellas Pharma
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.